Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation

Blood

Volumn 108, Issue 7, 2006, Pages 2173-2181

  Szpurka, Hadrian ^b   Tiu, Ramon ^b   Murugesan, Gurunathan ^b   Aboudola, Samer ^b   Hsi, Eric D ^b   Theil, Karl S ^b   Sekeres, Mikkael A ^b   Maciejewski, Jaroslaw P ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

JANUS KINASE 2; STAT5 PROTEIN;

ARTICLE; BLOOD SAMPLING; BONE MARROW; CLINICAL FEATURE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MYELOFIBROSIS; PHENOTYPE; POLYCYTHEMIA VERA; PREVALENCE; PRIORITY JOURNAL; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

EID: 33749325187     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-02-005751     Document Type: Article

References (31)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Hematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
2. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779-1790.
3. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054-1061.
4. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387-397.
5. Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood. 2005;106:2162-2168.
6. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434:1144-1148.
7. Wolanskyj AP, Lasho TL, Schwager SM, et al. JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance. Br J Haematol. 2005;131:208-213.
8. Ohyashiki K, Aota Y, Akahane D, et al. The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients. Leukemia. 2005;19:2359-2360.
9. Vizmanos JL, Ormazabal C, Larrayoz MJ, Cross NC, Calasanz MJ. JAK2 V617F mutation in classic chronic myeloproliferative diseases: a report on a series of 349 patients. Leukemia. 2006;20:534-535.
10. Cheung B, Radia D, Pantelidis P, Yadegarfar G, Harrison C. The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br J Haematol. 2006;132:244-245.
11. Passamonti F, Rumi E, Pietra D, et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34-positive cells into peripheral blood in myeloproliferative disorders. Blood. 2006;107:3676-3682.
12. Steensma DP, Dewald GW, Lasho TL, et al. The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. Blood. 2005;106:1207-1209.
13. Levine RL, Loriaux M, Huntly BJ, et al. The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia. Blood. 2005;106:3377-3379.
14. Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849GT is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood. 2005;106:3370-3373.
15. Johan MF, Goodeve AC, Bowen DT, Frew ME, Reilly JT. JAK2 V617F mutation is uncommon in chronic myelomonocytic leukaemia. Br J Haematol. 2005;130:968.
16. Van Etten RA, Shannon KM. Focus on myeloproliferative diseases and myelodysplastic syndromes. Cancer Cell. 2004;6:547-552.
17. Perez SI, Perez CA, Menarguez PJ, et al. Sideroblastic anaemia with reactive thrombocytosis versus myelodysplastic/myeloproliferative disease. Leuk Lymphoma. 2003;44:557-559.
18. Cabello AI, Collado R, Ruiz MA, et al. A retrospective analysis of myelodysplastic syndromes with thrombocytosis: reclassification of the cases by WHO proposals. Leuk Res. 2005;29:365-370.
19. List AF, Vardiman J, Issa JP, DeWitte TM. Myelodysplastic syndromes. Hematology. (Am Soc Hematol Educ Program.) 2004;297-317.
20. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088.
21. Roder S, Steimle C, Meinhardt G, Pahl HL. STAT3 is constitutively active in some patients with Polycythemia rubra vera. Exp Hematol. 2001;29:694-702.
22. Wlodarski MW, O'keefe C, Howe EC, et al. Pathologic clonal cytotoxic T-cell responses: non-random nature of the T-cell-receptor restriction in large granular lymphocyte leukemia. Blood. 2005;106:2769-2780.
23. Murugesan G, Aboudola S, Szpurka H, et al. Identification of the JAK2 V617F mutation in chronic myeloproliferative disorders using FRET probes and melting curve analysis. Am J Clin Pathol. 2006;125:625-633.
24. Aboudola S, Szpurka H, Murugesan G, et al. Megakaryocytic nuclear phospho-STAT5 staining in non-CML myeloproliferative disorders correlates with JAK2 V617F [abstract]. Mod Pathol. 2006;19:214A.
25. Sulong S, Case M, Minto L, et al. The V617F mutation in Jak2 is not found in childhood acute lymphoblastic leukaemia. Br J Haematol. 2005;130:964-965.
26. Tono C, Xu G, Toki T, et al. JAK2 Val617Phe activating tyrosine kinase mutation in juvenile myelomonocytic leukemia. Leukemia. 2005;19:1843-1844.
27. Frohling S, Lipka DB, Kayser S, et al. Rare occurrence of the JAK2 V617F mutation in AML subtypes M5, M6, and M7. Blood. 2006;107:1242-1243.
28. Imada K, Leonard WJ. The Jak-STAT pathway. Mol Immunol. 2000;37:1-11.
29. Kisseleva T, Bhattacharya S, Braunstein J, Schindler CW. Signaling through the JAK/STAT pathway, recent advances and future challenges. Gene. 2002;285:1-24.
30. Stocklin E, Wissler M, Gouilleux F, Groner B. Functional interactions between Stat5 and the glucocorticoid receptor. Nature. 1996;383:726-728.
31. Tsitoura DC, Rothman PB. Enhancement of MEK/ERK signaling promotes glucocorticoid resistance in CD4+ T cells. J Clin Invest. 2004;113:619-627.